Table 1.

Main characteristics of the eligible studies in the meta-analysis.

Study	No. patients		Period	Region	Design, center	Inclusion criteria	Stent type	Follow-up, years
	PCI	CABG
Aoki et al. 17	69	73	1997–1998	19 countries	Post-hoc analysis of RCT, multi	MVD, Ccr <60 ml/min	BMS	5
Chang et al. 18	7049	7049	1997–2009	USA	PSM registry, multi	MVD, on dialysis	BMS/DES	1.7 (median)
Chang et al. 19	1458	1458	1996–2008	USA	PSM registry, multi	MVD, eGFR <60 ml/min per 1.73 m2, not on dialysis	BMS/DES	3.9 (median)
Bangalore et al. 20	2960	2960	2008–2011	USA	PSM registry, multi	MVD, eGFR <60 ml/min per 1.73 m2	EES	2.9 (mean)
Chan et al. 21	893	893	2008–2011	Canada	PSM registry, multi	MVD, Ccr <60 ml/min	DES	1.8 (mean)
Komiya et al. 22	77	77	2005–2007	Japan	PSM registry, multi	MVD, eGFR <30 ml/min per 1.73 m2, not on dialysis	BMS/DES	2.5 (median)
Baber et al. 23	225	226	2005–2010	18 countries	Post-hoc analysis of RCT, multi	MVD, diabetes, eGFR <60 ml/min per 1.73 m2	PES/SES	3.8 (median)
Giustino et al. 24	177	184	2010–2014	17 countries	Post-hoc analysis of RCT, multi	LM, eGFR <60 ml/min per 1.73 m2	EES	3 (median)
Lima et al. 25	47	49	1995–2000	Brazil	Post-hoc analysis of RCT, single	MVD, eGFR <60 ml/min per 1.73 m2	BMS	9.4 (median)
Milojevic et al. 26	158	151	2005–2007	17 countries	Post-hoc analysis of RCT, multi	LM/MVD, eGFR <60 ml/min per 1.73 m2	PES	5
Gaipov et al. 27	104	104	2007–2014	USA	PSM registry, multi	MVD, on dialysis	BMS/DES	1.5 (median)

BMS, bare-metal stent; CABG, coronary artery bypass grafting; Ccr, creatinine clearance; DES, drug-eluting stent; EES, everolimus-eluting stent; eGFR, estimated glomerular filtration rate; LM, left main; MVD, multivessel disease; PCI, percutaneous coronary intervention; PES, paclitaxel-eluting stent; PSM, propensity-score matching; RCT, randomized controlled trial.